002940 昂利康
午间休市 10-13 11:30:00
资讯
新帖
简况
股市必读：昂利康新发布《关于增加2026年度日常关联交易预计额度的公告》
证券之星 · 10-12 01:17
股市必读：昂利康新发布《关于增加2026年度日常关联交易预计额度的公告》
昂利康（002940）10月9日主力资金净卖出2368.15万元
证券之星 · 10-09
昂利康（002940）10月9日主力资金净卖出2368.15万元
昂利康（002940）10月8日主力资金净买入4821.61万元
证券之星 · 10-08
昂利康（002940）10月8日主力资金净买入4821.61万元
昂利康（002940）9月30日主力资金净买入1028.34万元
证券之星 · 09-30
昂利康（002940）9月30日主力资金净买入1028.34万元
股市必读：昂利康新发布《关于第四届董事会第二十二次会议决议的公告》
证券之星 · 09-24
股市必读：昂利康新发布《关于第四届董事会第二十二次会议决议的公告》
昂利康创新药引进项目告吹：授权合作折戟背后，主业承压研发布局遇变数
新浪证券 · 09-11
昂利康创新药引进项目告吹：授权合作折戟背后，主业承压研发布局遇变数
昂利康（002940）披露关于终止《战略合作协议之授权许可协议》的公告，9月7日股价下跌3.46%
证券之星 · 09-07
昂利康（002940）披露关于终止《战略合作协议之授权许可协议》的公告，9月7日股价下跌3.46%
转型阵痛的昂利康：传统业务增长失速，豪赌创新药前景未明
市场资讯 · 09-07
转型阵痛的昂利康：传统业务增长失速，豪赌创新药前景未明
昂利康(002940.SZ)终止《战略合作协议之授权许可协议》
智通财经 · 09-06
昂利康(002940.SZ)终止《战略合作协议之授权许可协议》
股市必读：昂利康新发布《关于为控股子公司向银行申请授信提供担保进展的公告》
证券之星 · 09-04
股市必读：昂利康新发布《关于为控股子公司向银行申请授信提供担保进展的公告》
昂利康（002940）2026年中报简析：净利润同比下降16.68%
证券之星 · 08-26
昂利康（002940）2026年中报简析：净利润同比下降16.68%
股市必读：昂利康中报 - 第二季度单季净利润同比下降25.49%
证券之星 · 08-26
股市必读：昂利康中报 - 第二季度单季净利润同比下降25.49%
昂利康(002940.SZ)发布半年度业绩，归母净利润5492.64万元，同比下降16.68%
智通财经 · 08-24
昂利康(002940.SZ)发布半年度业绩，归母净利润5492.64万元，同比下降16.68%
昂利康（002940）披露2026年半年度报告，8月24日股价下跌4.17%
证券之星 · 08-24
昂利康（002940）披露2026年半年度报告，8月24日股价下跌4.17%
股市必读：昂利康新发布《2025年度向特定对象发行A股股票募集说明书（注册稿）》
证券之星 · 08-24
股市必读：昂利康新发布《2025年度向特定对象发行A股股票募集说明书（注册稿）》
昂利康最新公告：向特定对象发行股票获证监会同意注册批复
证券之星 · 08-20
昂利康最新公告：向特定对象发行股票获证监会同意注册批复
股市必读：昂利康新发布《关于参与第十二批全国药品集中带量采购拟中选的公告》
证券之星 · 08-03
股市必读：昂利康新发布《关于参与第十二批全国药品集中带量采购拟中选的公告》
昂利康最新公告：西格列汀二甲双胍缓释片等3个产品拟中选第十二批国家集采
证券之星 · 08-02
昂利康最新公告：西格列汀二甲双胍缓释片等3个产品拟中选第十二批国家集采
昂利康最新公告：获得洛索洛芬钠凝胶贴膏药品注册证书
证券之星 · 07-24
昂利康最新公告：获得洛索洛芬钠凝胶贴膏药品注册证书
7月24日昂利康跌6.63%，国泰海通新锐量化选股混合A基金重仓该股
证券之星 · 07-24
7月24日昂利康跌6.63%，国泰海通新锐量化选股混合A基金重仓该股
加载更多
公司概况
公司名称：
浙江昂利康制药股份有限公司
所属行业：
医药制造业
上市日期：
2018-10-23
主营业务：
浙江昂利康制药股份有限公司的主营业务是化学原料药、化学制剂及特色中间体系列产品的研发、生产和销售。公司的主要产品是口服头孢类抗生素原料药、alpha酮酸原料药、吸入用麻醉原料药、抗雄性激素中间体。
发行价格：
23.07
{"stockData":{"symbol":"002940","market":"SZ","secType":"STK","nameCN":"昂利康","latestPrice":21.87,"timestamp":1791867006000,"preClose":22.62,"halted":0,"volume":4605800,"delay":0,"changeRate":-0.0332,"floatShares":185000000,"shares":202000000,"eps":0.5674,"marketStatus":"午间休市","change":-0.75,"latestTime":"10-13 11:30:00","open":22.31,"high":22.4,"low":21.51,"amount":100000000,"amplitude":0.0393,"askPrice":21.87,"askSize":6,"bidPrice":21.86,"bidSize":25,"shortable":0,"etf":0,"ttmEps":0.5674,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791867600000},"marketStatusCode":3,"adr":0,"adjPreClose":22.62,"symbolType":"stock","openAndCloseTimeList":[[1791855000000,1791862200000],[1791867600000,1791874800000]],"highLimit":24.88,"lowLimit":20.36,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":201728186,"isCdr":false,"pbRate":2.76,"roa":"--","peRate":38.544237,"roe":"3.33%","epsLYR":0.62,"committee":-0.279503,"marketValue":4412000000,"turnoverRate":0.0249,"status":1,"floatMarketCap":4039000000},"requestUrl":"/m/hq/s/002940","defaultTab":"news","newsList":[{"id":"2674432808","title":"股市必读：昂利康新发布《关于增加2026年度日常关联交易预计额度的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674432808","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674432808?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:17","pubTimestamp":1791739027,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，昂利康报收于23.2元，下跌2.89%，换手率5.37%，成交量9.92万手，成交额2.29亿元。当日关注点交易信息汇总：10月9日主力资金净流出2368.15万元，占总成交额10.33%。公司公告汇总：昂利康增加2026年度日常关联交易预计额度，总额预计不超过1,808万元（不含税），调整事项在经营管理层决策权限内，无需提交董事会或股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000412.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674315358","title":"昂利康（002940）10月9日主力资金净卖出2368.15万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674315358","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674315358?lang=zh_cn&edition=full","pubTime":"2026-10-09 15:33","pubTimestamp":1791531234,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月9日收盘，昂利康报收于23.2元，下跌2.89%，换手率5.37%，成交量9.92万手，成交额2.29亿元。昂利康主营业务：医药的生产制造业务,主要包括化学原料药、化学制剂及特色中间体系列产品的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900018914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673021890","title":"昂利康（002940）10月8日主力资金净买入4821.61万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673021890","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673021890?lang=zh_cn&edition=full","pubTime":"2026-10-08 15:28","pubTimestamp":1791444490,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，昂利康报收于23.89元，上涨4.05%，换手率8.08%，成交量14.93万手，成交额3.57亿元。昂利康主营业务：医药的生产制造业务,主要包括化学原料药、化学制剂及特色中间体系列产品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800014176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671279818","title":"昂利康（002940）9月30日主力资金净买入1028.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671279818","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671279818?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:28","pubTimestamp":1790753314,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月30日收盘，昂利康报收于22.96元，上涨3.28%，换手率4.17%，成交量7.7万手，成交额1.76亿元。昂利康主营业务：医药的生产制造业务,主要包括化学原料药、化学制剂及特色中间体系列产品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000019040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669438188","title":"股市必读：昂利康新发布《关于第四届董事会第二十二次会议决议的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669438188","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669438188?lang=zh_cn&edition=full","pubTime":"2026-09-24 01:28","pubTimestamp":1790184494,"startTime":"0","endTime":"0","summary":"公司公告汇总：董事会审议通过以自有资金5,040万元对广东永涛药业有限公司增资并取得其40%股权。关于第一期员工持股计划存续期展期的公告浙江昂利康制药股份有限公司于2026年9月22日召开第四届董事会第二十二次会议，审议通过《关于第一期员工持股计划存续期展期的议案》，同意将第一期员工持股计划存续期展期12个月，至2027年11月2日。该员工持股计划目前持有公司股份4,331,150股，占总股本的2.15%，尚未出售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400002036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544925","title":"昂利康创新药引进项目告吹：授权合作折戟背后，主业承压研发布局遇变数","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544925","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666544925?lang=zh_cn&edition=full","pubTime":"2026-09-11 15:35","pubTimestamp":1789112100,"startTime":"0","endTime":"0","summary":"9 月 6 日，昂利康发布公告宣布终止与亚飞生物、亲合力的 IMD\u001e1005肿瘤抗体药物授权许可合作。02主业盈利出现下滑，创新转型面临双重考验创新药引进受挫的同时，昂利康主业经营已经显现压力。原料药业务是昂利康的基本盘，业绩下滑说明核心主业易受行业周期、市场供需波动冲击，自身抗周期能力有待加强。未来昂利康既要稳固原料药基本盘，也需要平衡好资金投入与管线风险，审慎推进授权引进类项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-09-11/doc-inirmvzx5384750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","LNGR","IBBQ","BK1161","BK1574","MEDX","BK0239","06978","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311764","title":"昂利康（002940）披露关于终止《战略合作协议之授权许可协议》的公告，9月7日股价下跌3.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665311764?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:44","pubTimestamp":1788774299,"startTime":"0","endTime":"0","summary":"截至2026年9月7日收盘，昂利康报收于25.95元，较前一交易日下跌3.46%，最新总市值为52.35亿元。近日，浙江昂利康制药股份有限公司披露《关于终止〈战略合作协议之授权许可协议〉的公告》。本次终止不影响公司正常生产经营及财务状况，不损害公司及股东利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700023003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665904373","title":"转型阵痛的昂利康：传统业务增长失速，豪赌创新药前景未明","url":"https://stock-news.laohu8.com/highlight/detail?id=2665904373","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665904373?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:08","pubTimestamp":1788768480,"startTime":"0","endTime":"0","summary":"证券之星注意到，2026年上半年，昂利康营收、净利双双下滑逾10%，传统业务中原料药收入持续缩水，特色中间体规模更是“腰斩”，成为主要拖累。传统业务增长失速、创新业务远水难解，昂利康能否在多重压力中突围，仍有待时间检验。昂利康提示风险称，肿瘤创新药产品各阶段的成功率相对于其他创新药低，风险较高，不确定性较大。昂利康如何在传统业务与创新药漫长培育期之间找到平衡，才是市场关注的焦点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-09-07/doc-iniqyvry5536300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","BK1161","002940","BK0239","IBBQ","MEDX","BK1574","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665235361","title":"昂利康(002940.SZ)终止《战略合作协议之授权许可协议》","url":"https://stock-news.laohu8.com/highlight/detail?id=2665235361","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665235361?lang=zh_cn&edition=full","pubTime":"2026-09-06 16:28","pubTimestamp":1788683331,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昂利康 发布公告，公司就IMD-1005药物分子与亚飞(上海)生物医药科技有限公司、上海亲合力生物医药科技股份有限公司于2025年8月26日签署了《战略合作协议之授权许可协议》。近日，公司收到亚飞生物及亲合力《关于终止<战略合作协议之授权许可协议>的通知函》。鉴于合作方前述战略调整，截至公告披露日，《战略合作协议之授权许可协议》所约定的生效条件未能成就，本次合作事项实质上已终止推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664137805","title":"股市必读：昂利康新发布《关于为控股子公司向银行申请授信提供担保进展的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664137805","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664137805?lang=zh_cn&edition=full","pubTime":"2026-09-04 01:01","pubTimestamp":1788454875,"startTime":"0","endTime":"0","summary":"公司公告汇总：昂利康为控股子公司动保科技向嵊州农商行提供4160万元连带责任保证，被担保方资产负债率达235.02%；公司实际担保余额3166.80万元，占2025年归母净资产1.95%。公司公告汇总关于为控股子公司向银行申请授信提供担保进展的公告浙江昂利康制药股份有限公司于2026年9月2日与浙江嵊州农村商业银行股份有限公司剡湖支行签署《最高额保证合同》，为控股子公司浙江昂利康动保科技有限公司向该行申请授信提供4160万元连带责任保证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400001615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","161121","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662509217","title":"昂利康（002940）2026年中报简析：净利润同比下降16.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662509217","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662509217?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:27","pubTimestamp":1787696827,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期昂利康发布2026年中报。根据财报显示，昂利康净利润同比下降16.68%。截至本报告期末，公司营业总收入6.27亿元，同比下降13.44%，归母净利润5492.64万元，同比下降16.68%。按单季度数据看，第二季度营业总收入2.87亿元，同比下降24.27%，第二季度归母净利润3727.16万元，同比下降25.49%。其他应收款变动幅度为158.3%,原因:截至报告期末昂利康胶囊股权转让款尚未全部收回。应付票据变动幅度为41.87%,原因:开具的银行承兑汇票支付货款增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600010111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752881","title":"股市必读：昂利康中报 - 第二季度单季净利润同比下降25.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752881","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662752881?lang=zh_cn&edition=full","pubTime":"2026-08-26 04:27","pubTimestamp":1787689630,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年第二季度单季度归母净利润3727.16万元，同比下降25.49%；扣非净利润2076.32万元，同比下降40.56%。公司公告汇总2026年半年度报告摘要浙江昂利康制药股份有限公司2026年半年度报告摘要显示，本报告期营业收入为627,033,693.79元，较上年同期减少13.44%；归属于上市公司股东的净利润为54,926,353.41元，同比减少16.68%；归属于上市公司股东的扣除非经常性损益的净利润为36,805,556.78元，同比减少15.77%；经营活动产生的现金流量净额为138,484,063.73元，同比增长57.38%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600007968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661277184","title":"昂利康(002940.SZ)发布半年度业绩，归母净利润5492.64万元，同比下降16.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661277184","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661277184?lang=zh_cn&edition=full","pubTime":"2026-08-24 23:20","pubTimestamp":1787584815,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昂利康(002940.SZ)发布2026年半年度报告，报告期内，公司实现营业总收入6.27亿元，同比下降13.44%;归属于上市公司股东的净利润5492.64万元，同比下降16.68%;归属于上市公司股东的扣除非经常性损益的净利润3680.56万元，同比下降15.77%;基本每股收益0.27元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"昂利康(002940.SZ)发布半年度业绩，归母净利润5492.64万元，同比下降16.68%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661272466","title":"昂利康（002940）披露2026年半年度报告，8月24日股价下跌4.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661272466","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661272466?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:43","pubTimestamp":1787582596,"startTime":"0","endTime":"0","summary":"近日，浙江昂利康制药股份有限公司披露《2026年半年度报告》。本报告期末总资产为2,975,889,883.53元，较上年度末增长0.85%；归属于上市公司股东的净资产为1,654,693,407.75元，较上年度末增长1.69%。公司控股股东和实际控制人在报告期内未发生变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400037926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661203243","title":"股市必读：昂利康新发布《2025年度向特定对象发行A股股票募集说明书（注册稿）》","url":"https://stock-news.laohu8.com/highlight/detail?id=2661203243","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661203243?lang=zh_cn&edition=full","pubTime":"2026-08-24 01:12","pubTimestamp":1787505133,"startTime":"0","endTime":"0","summary":"公司公告汇总：昂利康收到证监会《关于同意向特定对象发行股票注册的批复》，批复有效期12个月。公司公告汇总2025年度向特定对象发行A股股票募集说明书（注册稿）浙江昂利康制药股份有限公司拟向特定对象发行A股股票，募集资金111,000.00万元，扣除发行费用后全部用于创新药研发项目；发行数量不超过60,518,455股，不超过发行前公司总股本的30%；发行对象为不超过35名符合资格的特定投资者，限售期6个月；本次发行不会导致公司控制权变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400000816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02827","BK1147","03130","83130","83188","BK0239","399300","82846","03188","159982","002940","07233","02846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660328392","title":"昂利康最新公告：向特定对象发行股票获证监会同意注册批复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660328392","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660328392?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:10","pubTimestamp":1787220627,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称，公司收到证监会出具的《关于同意浙江昂利康制药股份有限公司向特定对象发行股票注册的批复》，同意公司向特定对象发行股票的注册申请。本次发行应严格按照报送深交所的申报文件和发行方案实施，批复自同意注册之日起12个月内有效。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000033253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656762348","title":"股市必读：昂利康新发布《关于参与第十二批全国药品集中带量采购拟中选的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656762348","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656762348?lang=zh_cn&edition=full","pubTime":"2026-08-03 01:58","pubTimestamp":1785693491,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，昂利康报收于24.34元，上涨3.97%，换手率5.31%，成交量9.84万手，成交额2.38亿元。公司公告汇总关于参与第十二批全国药品集中带量采购拟中选的公告浙江昂利康制药股份有限公司及子公司福建海西联合药业有限公司参与第十二批全国药品集中带量采购，吸入用七氟烷、西格列汀二甲双胍缓释片、沙库巴曲缬沙坦钠片拟中选。2025年度上述产品销售额合计约5,068万元，占公司营业总收入的3.56%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656312744","title":"昂利康最新公告：西格列汀二甲双胍缓释片等3个产品拟中选第十二批国家集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2656312744","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656312744?lang=zh_cn&edition=full","pubTime":"2026-08-02 16:20","pubTimestamp":1785658824,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称，公司及子公司海西药业参与第十二批全国药品集中带量采购，西格列汀二甲双胍缓释片、沙库巴曲缬沙坦钠片及吸入用七氟烷拟中选。上述产品2025年度销售额合计约5068万元，占公司营收的3.56%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200006700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653083549","title":"昂利康最新公告：获得洛索洛芬钠凝胶贴膏药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2653083549","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653083549?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:40","pubTimestamp":1784886056,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称，公司收到国家药监局签发的洛索洛芬钠凝胶贴膏《药品注册证书》，该药品用于骨关节炎、肌肉痛、外伤后的肿胀疼痛等消炎镇痛。本次获批视同通过一致性评价，将进一步丰富公司仿制药产品管线，增强综合竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400030860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653470097","title":"7月24日昂利康跌6.63%，国泰海通新锐量化选股混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653470097","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653470097?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:49","pubTimestamp":1784882982,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日昂利康跌6.63%创60日新低，收盘报23.65元，换手率6.39%，成交量11.83万手，成交额2.86亿元。国泰海通新锐量化选股混合A目前规模为0.32亿元，最新净值1.2107，较上一交易日上涨1.25%。国泰海通新锐量化选股混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0188","BK0276","BK1564","02611","002940","BK1147","601211","BK0012","BK0184","BK0239","BK0028","BK0201"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791867025082,"stockEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0204},{"period":"3month","weight":-0.1403},{"period":"6month","weight":-0.2974},{"period":"1year","weight":-0.3985},{"period":"ytd","weight":-0.3217}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.0234},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0571},{"period":"1year","weight":-0.0256},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江昂利康制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"36257人(较上一季度减少9.88%)","perCapita":"5093股","listingDate":"2018-10-23","address":"浙江省绍兴市嵊州市嵊州大道北1000号","registeredCapital":"20172万元","survey":" 浙江昂利康制药股份有限公司的主营业务是化学原料药、化学制剂及特色中间体系列产品的研发、生产和销售。公司的主要产品是口服头孢类抗生素原料药、alpha酮酸原料药、吸入用麻醉原料药、抗雄性激素中间体。","listedPrice":23.07},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昂利康(002940)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昂利康(002940)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昂利康,002940,昂利康股票,昂利康股票老虎,昂利康股票老虎国际,昂利康行情,昂利康股票行情,昂利康股价,昂利康股市,昂利康股票价格,昂利康股票交易,昂利康股票购买,昂利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昂利康(002940)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昂利康(002940)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}